A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host

Christian M. Harding(Omni Sciences (United States)), Mario F. Feldman(University of Alberta)
Nature Communications
February 21, 2019
Cited by 92


Related Papers